Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Trend Edge Setup Score
Trend Edge rates PCSA Bearish with a Setup Score of 52, net conviction 43, actionability 62. How the Setup Score works →
Total Setup Score
52
Directional Bias
Bearish
Net Conviction
43
Actionability
62 (in range)
Key signals behind this score
40wk Downtrend — falling+below (sma 2.94 vs px 2.06)
Fresh Breakdown — 10wk turn 12w · aligned 34w
80wk Downtrend — falling+below (sma 5.02 vs px 2.06)
200wk Downtrend — falling+below (sma 127 vs px 2.06)
Short Attack — velZ +2.22 · age 26w×1.00 · 8.17%
Seasonal Headwind — october med -6.2% (mag 2/3) · posClose 25.00% (rel 2/3) · n12 ×0.75 = 8.3
Earnings Headwind — ER in 0d · w1 med -1.1% (mag 0/3) · winRate 37.5% (rel 1/3) · n32
About Processa Pharmaceuticals Inc
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: October 10, 2017
Headquarters: 601 21st Street, Vero Beach, FL, United States, 32960
Founder-Led: Yes — David Young (President, Research & Development and Founder), Sian Bigora (Chief Development and Regulatory Officer and Founder), Patrick Lin (Chief Business & Strategy Officer and Founder), Wendy Guy (Chief Administrative Officer & Corporate Secretary and Founder)
Key Metrics
Current Price
$2.06
Market Cap
$5.9M
Float
2.5M
Shares Outstanding
2.8M
P/E (TTM)
3.25
Price/Sales (TTM)
1,320.06
vs. Analyst Target
+1113.6% to analyst PT
Dividend Rate
None
Analyst Target Price
$25.00 (1 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
N/A
-$19.0M
-$882,062
-$14.3M
2021
N/A
-$11.4M
-$875,349
-$10.8M
2022
N/A
-$27.4M
-$874,013
-$26.6M
2023
N/A
-$11.1M
-$222
-$11.1M
2024
N/A
-$11.9M
-$782
-$11.8M
2025
N/A
-$13.6M
-$1,204
-$13.6M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Sep 2025
N/A
-$3.4M
Dec 2025
N/A
-$3.4M
Mar 2026
N/A
-$3.4M
Jun 2026
N/A
-$3.3M
Ownership & Float
Insider Ownership
14.8%
Institutional Ownership
18.7%
Short Float
8.6%
% of All Funds Holding
0.14%
Number of Funds Holding
12
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$2.24
Near-term / short-term trend
Weekly
40-Week SMA
$2.94
Medium-term trend
Weekly
80-Week SMA
$5.02
Cyclical trend (business cycle)
Weekly
200-Week SMA
$126.69
Secular trend (multi-year)
Monthly
10-Month SMA
$2.84
Near-term monthly trend
Monthly
20-Month SMA
$5.55
Medium-term monthly trend
Monthly
40-Month SMA
$59.08
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$6.30
resistance
3.64x
7 months ago
$30.20
resistance
1.06x
19 months ago
Historical Earnings Reactions (32 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
0.78%
0.00%
34.38%
9.17%
-5.06%
1 Day
-0.98%
0.00%
31.25%
8.73%
-13.16%
1 Week
0.61%
-1.06%
37.50%
27.08%
-22.33%
2 Weeks
-4.29%
-9.63%
32.26%
50.83%
-40.00%
1 Month
0.40%
-8.68%
35.48%
99.05%
-41.29%
Next earnings: August 6, 2026
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
-21.0%
8.3%
12
Feb
-0.2%
41.7%
12
Mar
-9.8%
25.0%
12
Apr
-1.6%
23.1%
13
May
-1.4%
38.5%
13
Jun
2.3%
38.5%
13
Jul
19.3%
38.5%
13
Aug
-7.4%
25.0%
12
Sep
4.3%
41.7%
12
Oct
-3.6%
25.0%
12
Nov
-1.5%
25.0%
12
Dec
1.4%
58.3%
12
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
0.36%
28.2%
589
Tuesday
0.88%
25.5%
646
Wednesday
0.03%
26.1%
643
Thursday
0.28%
25.7%
630
Friday
-0.25%
24.1%
626
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 18.7%
Insider Transactions — Smart Summary
Total insider ownership: 14.8%
Founder-led management: David Young (President, Research & Development and Founder), Sian Bigora (Chief Development and Regulatory Officer and Founder), Patrick Lin (Chief Business & Strategy Officer and Founder), Wendy Guy (Chief Administrative Officer & Corporate Secretary and Founder)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Processa Pharmaceuticals Inc
(PCSA) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.